UCLA scientists reported a next‑generation CAR‑T cell engineered to overcome immunosuppressive barriers in solid tumors, addressing a principal limitation that has constrained CAR‑T success outside blood cancers. The engineered cells incorporate modifications to resist tumor microenvironment factors and enhance intratumoral persistence in preclinical models. The technology advances the field’s effort to translate adoptive cell therapy into common solid malignancies. If safety and manufacturability scale in human trials, this approach could shift investment and clinical focus toward engineered cell platforms tailored for the solid‑tumor microenvironment.